Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma - Concepedia

Concepedia

Publication | Open Access

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

DOI Full Paper Access

41

Citations

22

References

2021

Year

Cara M. Kenney, Tricia Kunst, Santhana Webb, Christina DeVisser, Christy Arrowood, Seth M. Steinberg, Niharika B. Mettu, Edward Kim, Udo Rudloff

Investigational New Drugs

References

	Year	Citations

Page 1